★ Analysts see FY2026 revenue reaching $1.4B — +39.0% growth in a single year.
Why Revenue Could Explode
01CARVYKTI quarterly sales performance versus consensus estimates and sequential growth trajectory
02Clinical trial data readouts for CARTITUDE-4 (second-line multiple myeloma) and other earlier-line studies that could expand addressable market from ~10,000 to ~40,000+ patients annually
03Manufacturing capacity announcements and vein-to-vein time improvements that signal ability to meet demand without slot constraints
04Competitive developments from Bristol Myers Squibb (Abecma, CC-92480), Caribou Biosciences (allogeneic CAR-T), and other BCMA-targeted therapies
05FDA regulatory decisions on label expansions and manufacturing site approvals
growth - investors are betting on CARVYKTI's potential to capture significant share of the $8B+ multiple myeloma market as it moves…
Rising interest rates negatively impact valuation multiples for pre-profitable biotech companies as investors discount future cash flows…
Watch on earnings: CARVYKTI quarterly net sales and year-over-year growth rate, Number of authorized treatment centers and active apheresis sites in US and Europe, Manufacturing slot availability and vein-to-vein median time from collection to infusion.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $1.4B to $1.8B as carvykti quarterly sales performance versus consensus estimates and sequential growth trajectory.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
